Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G. van der Helm LH, et al. Among authors: hoogendoorn m. Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8. Br J Haematol. 2011. PMID: 21981697 Free article. Clinical Trial.
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
van der Helm LH, Veeger NJ, Kooy Mv, Beeker A, de Weerdt O, de Groot M, Alhan C, Hoogendoorn M, Laterveer L, van de Loosdrecht AA, Koedam J, Vellenga E, Huls G. van der Helm LH, et al. Among authors: hoogendoorn m. Leuk Res. 2013 Aug;37(8):877-82. doi: 10.1016/j.leukres.2013.03.022. Epub 2013 Apr 28. Leuk Res. 2013. PMID: 23628552 Free article.
Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.
Boslooper K, Kibbelaar R, Storm H, Veeger NJ, Hovenga S, Woolthuis G, van Rees B, de Graaf E, van Roon E, Kluin-Nelemans HC, Joosten P, Hoogendoorn M. Boslooper K, et al. Among authors: hoogendoorn m. Leuk Lymphoma. 2014 Mar;55(3):526-32. doi: 10.3109/10428194.2013.810737. Epub 2013 Jul 29. Leuk Lymphoma. 2014. PMID: 23734653
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, Kibbelaar RE, Veldhuis GJ, van Kamp H, van Rees B, Kluin-Nelemans HC, Veeger NJ, van Roon EN. Wieringa A, et al. Among authors: hoogendoorn m. Br J Haematol. 2014 May;165(4):489-96. doi: 10.1111/bjh.12765. Epub 2014 Feb 7. Br J Haematol. 2014. PMID: 24754632 Free article.
Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.
de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. de Waal EG, et al. Among authors: hoogendoorn m. Br J Haematol. 2015 Dec;171(5):720-5. doi: 10.1111/bjh.13653. Epub 2015 Sep 11. Br J Haematol. 2015. PMID: 26358087 Free article.
The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.
Oortgiesen BE, van Roon EN, Joosten P, Kibbelaar RE, Storm H, Hovenga S, van Rees B, Woolthuis G, Veeger N, de Waal EG, Hoogendoorn M. Oortgiesen BE, et al. Among authors: hoogendoorn m. Eur J Clin Pharmacol. 2017 Jun;73(6):771-778. doi: 10.1007/s00228-017-2227-1. Epub 2017 Mar 3. Eur J Clin Pharmacol. 2017. PMID: 28258356
Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology.
Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger NJGM, Joosten P, Storm H, van Roon EN, Hoogendoorn M. Kibbelaar RE, et al. Among authors: hoogendoorn m. Eur J Cancer. 2017 Nov;86:178-185. doi: 10.1016/j.ejca.2017.09.007. Epub 2017 Oct 6. Eur J Cancer. 2017. PMID: 28992561 Review.
247 results